Literature DB >> 29182255

More on Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma.

Pierre Tiberghien1,2, Eric Deconinck1, Oliver Adotevi1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 29182255     DOI： 10.1056/NEJMc1712460

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  A phase I study of CAR-T bridging HSCT in patients with acute CD19+ relapse/refractory B-cell leukemia.

Authors:  Yongyong Ma; Shenghui Zhang; Hongliang Fang; Kang Yu; Songfu Jiang
Journal:  Oncol Lett       Date:  2020-07-16       Impact factor: 3.111

2.  Relapsed and refractory primary CNS lymphoma: treatment approaches in routine practice.

Authors:  Prakash Ambady; Nancy D Doolittle; Christopher P Fox
Journal:  Ann Lymphoma       Date:  2021-09

Review 3.  Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions.

Authors:  Alaa Alnefaie; Sarah Albogami; Yousif Asiri; Tanveer Ahmad; Saqer S Alotaibi; Mohammad M Al-Sanea; Hisham Althobaiti
Journal:  Front Bioeng Biotechnol       Date:  2022-06-22

Review 4.  Combination therapy: A feasibility strategy for CAR-T cell therapy in the treatment of solid tumors.

Authors:  Jinjing Xu; Yali Wang; Jing Shi; Juan Liu; Qingguo Li; Longzhou Chen
Journal:  Oncol Lett       Date:  2018-06-11       Impact factor: 3.111
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.